Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is a common liver disease linked to metabolic dysfunction. While often associated with obesity, MASLD also affects lean individuals, raising questions about its underlying mechanisms and clinical implications. This paper aims to review the latest insights into MASLD, with a specific focus on lean individuals, exploring its prevalence, pathogenesis, cardiovascular risk and treatment strategies. A systematic review was conducted using PubMed and Google Scholar to examine recent studies on MASLD, particularly in lean patients. Key terms included ‘metabolic dysfunction-associated steatotic liver disease’ and ‘nonalcoholic fatty liver disease.’ Approximately 10%–20% of MASLD cases occur in lean individuals, who exhibit impaired glucose metabolism and visceral fat accumulation. Despite fewer metabolic comorbidities, lean MASLD patients show similar disease severity and poorer outcomes compared to obese patients. The condition is linked to insulin resistance, genetic factors, and alterations in the gut microbiome. Cardiovascular risk in lean MASLD patients is lower than in obese counterparts, but advanced age and hepatic fibrosis increase the likelihood of cardiovascular complications. Moreover, lean patients face higher overall mortality rates, with hepatocellular carcinoma more prevalent among them. Lean MASLD remains an under-recognized but significant condition. Early diagnosis, personalized treatment approaches, and further research are essential for improving outcomes. Future studies should focus on refining diagnostic tools, identifying biomarkers, and developing tailored therapies for lean patients.

• Publication year

  2025

• Venue

  Polish Annals of Medicine

• Publication date

  2025-11-05

• Fields of study

  Not labeled

• Identifiers
  DOI 10.29089/paom/203734
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiovascular Morbidity and Mortality in Lean vs. Non-Lean MASLD: A Comprehensive Meta-Analysis.

  2024cited by this paper
• Long-term outcomes and risk modifiers of metabolic dysfunction-associated steatotic liver disease between lean and non-lean populations

  2024cited by this paper
• Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review

  2024cited by this paper
• Comparison of risk factors between lean and non-lean MASLD in individuals with type 2 diabetes: a multicenter study.

  2024cited by this paper
• Liver and cardiovascular outcomes in lean non-alcoholic fatty liver disease: an updated systematic review and meta-analysis of about 1 million individuals

  2024cited by this paper
• EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).

  2024cited by this paper
• Author Correction: Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population

  2024cited by this paper
• Gender Differences in Liver Steatosis and Fibrosis in Overweight and Obese Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease before and after 8 Weeks of Very Low-Calorie Ketogenic Diet

  2024cited by this paper
• Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions

  2024cited by this paper
• Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with non-alcoholic fatty liver disease (NAFLD).

  2023cited by this paper
• Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities

  2023cited by this paper
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

  2023cited by this paper
• MASLD treatment—a shift in the paradigm is imminent

  2023cited by this paper
• Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease

  2023cited by this paper
• Epidemiology and prevalence of lean nonalcoholic fatty liver disease and associated cirrhosis, hepatocellular carcinoma, and cardiovascular outcomes in the United States: a population‐based study and review of literature

  2022cited by this paper
• Nonalcoholic fatty liver disease versus metabolic-associated fatty liver disease: Prevalence, outcomes and implications of a change in name

  2022cited by this paper
• AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.

  2022cited by this paper
• Recent advances in lean NAFLD.

  2022cited by this paper
• Lean non-alcoholic fatty liver disease (Lean-NAFLD) and the development of metabolic syndrome: a retrospective study

  2022cited by this paper
• Nonalcoholic Fatty Liver Disease in Lean Subjects: Associations With Metabolic Dysregulation and Cardiovascular Risk—A Single-Center Cross-Sectional Study

  2021cited by this paper
• Circulating histone signature of human lean metabolic-associated fatty liver disease (MAFLD)

  2020cited by this paper
• Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease

  2020cited by this paper
• Lean Patients with Non-Alcoholic Fatty Liver Disease Have a Severe Histological Phenotype Similar to Obese Patients

  2018cited by this paper
• Prevalence and Severity of Nonalcoholic Fatty Liver Disease in Non-Obese Patients: A Population Study Using Proton-Magnetic Resonance Spectroscopy

  2015cited by this paper
• PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome

  2014cited by this paper

• No citing papers are available for this paper.